Savara, Inc. (SVRA)

[lux1]

2018 year of trials and results.

P3 Molgradex in PAP ends in Q1 and results in Q4.
P3 Aerovanc in MRSA in Cystic Fibrosis continues.
P2 Molgradex in antibiotic-resistant NTM lung infection starts in Q1
P2 Aironite in Heart Failure pEF results Q1-Q2.
P2 Aironite in Heart Failure continues.
P2 Aironite in Cystic Fibrosis and P. aeruginosa infection results in Q1

if Aironite will show effectiveness as expected the target price can easily double due to very large market of heart failure.